For the Inventor, By the Inventor

Enter inventor name

New Providence, NJ, United States of America

Philippe L Durette

USPTO Granted Patents = 68

EPO Patents = 2

Average Co-Inventor Count = 2.3

ph-index = 17

Forward Citations = 771(Granted Patents)

Forward Citations (Not Self Cited) = 747(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Rahway, NJ (US) (1999)
New Providence, NJ (US) (1980 - 2012)

Company Filing History:

66 out of 4,770

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

where one patent can have more than one assignee

Years Active: 1980-2012

Loading Chart...

Loading Chart...

Areas of Expertise:

Nucleoside Phosphoramidates

Cell Adhesion Inhibitors

Nitric Oxide Synthase Inhibitors

Anti-inflammatory Agents

Antidegenerative Agents

Tachykinin Receptor Antagonists

Aza Androstane Inhibitors

Steroidal Glycolipids

Dipeptidyl Derivatives

Host Resistance Enhancers

Hydroxyazabenzo Derivatives

Cyclic Amidine Analogs

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8148349 - Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection (2012-04-03),

2. 8071568 - Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection (2011-12-06),

3. 6903075 - Heterocyclic amide compounds as cell adhesion inhibitors (2005-06-07),

4. 6645939 - Substituted &bgr;-alanine derivatives as cell adhesion inhibitors (2003-11-11),

5. 6291511 - Biarylalkanoic acids as cell adhesion inhibitors (2001-09-18),

6. 6221888 - Sulfonamides as cell adhesion inhibitors (2001-04-24),

7. 6204273 - 16-substituted-4-aza-androstane 5-&agr;-reductase isozyme 1 inhibitors (2001-03-20),

8. 6090785 - Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents (2000-07-18),

9. 5972975 - Substituted 2-aminopyridines as inhibitors of nitric oxide synthase (1999-10-26),

10. 5952321 - Substituted azetidinones as anti-inflammatory and antidegenerative agents (1999-09-14),

11. 5932551 - Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative (1999-08-03),

12. 5929094 - Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists (1999-07-27),

13. 5910497 - 16-pyrazinyl-substituted-4-aza-androstane 5-.alpha.-reductase isozyme 1 (1999-06-08),

14. 5908842 - Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase (1999-06-01),

15. 5821261 - Substituted saturated aza heterocycles as inhibitors of nitric oxide (1998-10-13),

Title: The Innovative Journey of Inventor Philippe L Durette

Introduction: Philippe L Durette, a visionary inventor based in New Providence, NJ, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Philippe L Durette holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices. His most recent patent focuses on a cutting-edge smart home automation system that revolutionizes the way we interact with our living spaces.

Career Highlights: With a career spanning over two decades, Philippe L Durette has established himself as a leading figure in the innovation landscape. He has worked with top research institutions and tech companies to bring his ideas to life, earning recognition for his creativity and problem-solving skills.

Collaborations: Throughout his career, Philippe L Durette has collaborated with renowned engineers, designers, and scientists to develop groundbreaking technologies. His ability to work effectively in multidisciplinary teams has led to the successful implementation of several innovative projects.

Conclusion: In conclusion, Philippe L Durette's passion for innovation and his relentless pursuit of excellence have cemented his reputation as a prolific inventor. His contributions to the world of technology continue to inspire and shape the future of innovation.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…